Synopsis
Synopsis
0
CEP/COS
0
JDMF
0
EU WC
0
VMF
0
EDQM
0
USP
0
JP
0
Others
0
FDF Dossiers
0
FDA Orange Book
0
Europe
0
Canada
0
Australia
0
South Africa
0
Listed Dossiers
DRUG PRODUCT COMPOSITIONS
0
US Patents
0
US Exclusivities
0
Health Canada Patents
US Medicaid
NA
Annual Reports
NA
Regulatory FDF Prices
NA
0
FDF
0
Data Compilation #PharmaFlow
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
1. (s)-4-((5,7-difluorochroman-4-yl)oxy)-n,n,2-trimethyl-1h-benzo(d)imidazole-6-carboxamide
2. 1h-benzimidazole-5-carboxamide, 7-(((4s)-5,7-difluoro-3,4-dihydro-2h-1-benzopyran-4-yl)oxy)-n,n,2-trimethyl-
3. 7-(((4s)-5,7-difluoro-3,4-dihydro-2h-chromen-4-yl)oxy)-n,n,2-trimethyl-1h-benzimidazole-5-carboxamide
1. 942195-55-3
2. Tegoprazan [inn]
3. W017g7if4s
4. Lxi-15028
5. (s)-4-((5,7-difluorochroman-4-yl)oxy)-n,n,2-trimethyl-1h-benzo[d]imidazole-6-carboxamide
6. 1h-benzimidazole-5-carboxamide, 7-(((4s)-5,7-difluoro-3,4-dihydro-2h-1-benzopyran-4-yl)oxy)-n,n,2-trimethyl-
7. Unii-w017g7if4s
8. Emixustat Hcl
9. (s)-4-((5,7-difluorochroman-4-yl)oxy)-n,n,2-trimethyl-1h-benzo(d)imidazole-6-carboxamide
10. 7-[[(4s)-5,7-difluoro-3,4-dihydro-2h-chromen-4-yl]oxy]-n,n,2-trimethyl-3h-benzimidazole-5-carboxamide
11. K-cab
12. Tegoprazan [who-dd]
13. Schembl2687723
14. Chembl4297583
15. Schembl19236298
16. Gtpl12008
17. (s)-7-((5,7-difluorochroman-4-yl)oxy)-n,n,2-trimethyl-1h-benzo(d)imidazole-5-carboxamide
18. Ex-a4304
19. Cj12420
20. Ac-36576
21. As-84160
22. Cj-12420
23. Hy-17623
24. Cs-0014702
25. E83739
26. Cj-12420; In-a001; Lxi-15028
27. Q27292116
28. (-)-4-[((4s)-5,7-difluoro-3,4-dihydro-2h-chromen-4-yl)oxy]-n,n,2-trimethyl-1h-benzimidazole-6-carboxamide
29. 7-(((4s)-5,7-difluoro-3,4-dihydro-2h-chromen-4-yl)oxy)-n,n,2-trimethyl-1h-benzimidazole-5-carboxamide
30. 7-[[(4s)-5,7-difluoro-3,4-dihydro-2h-1-benzopyran-4-yl]oxy]-n,n,2-trimethyl-1h-benzimidazole-5-carboxamide
31. 8bn
| Molecular Weight | 387.4 g/mol |
|---|---|
| Molecular Formula | C20H19F2N3O3 |
| XLogP3 | 3.2 |
| Hydrogen Bond Donor Count | 1 |
| Hydrogen Bond Acceptor Count | 6 |
| Rotatable Bond Count | 3 |
| Exact Mass | 387.13944780 g/mol |
| Monoisotopic Mass | 387.13944780 g/mol |
| Topological Polar Surface Area | 67.4 Ų |
| Heavy Atom Count | 28 |
| Formal Charge | 0 |
| Complexity | 581 |
| Isotope Atom Count | 0 |
| Defined Atom Stereocenter Count | 1 |
| Undefined Atom Stereocenter Count | 0 |
| Defined Bond Stereocenter Count | 0 |
| Undefined Bond Stereocenter Count | 0 |
| Covalently Bonded Unit Count | 1 |
A - Alimentary tract and metabolism
A02 - Drugs for acid related disorders
A02B - Drugs for peptic ulcer and gastro-oesophageal reflux disease (gord)
A02BC - Proton pump inhibitors
A02BC09 - Tegoprazan
Tegoprazan works as a potassium-competitive acid blocker that is potent and highly selective. Its mechanism of action is different from that of the proton-pump inhibitors as this drug does not require conversion into an active form and can directly inhibit H+/K+ATPase in a reversible and K+competitive way. This is because it is an acid-resistant weak base with the ability to remain in the highly acidic canaliculi of gastric parietal cells.
API SUPPLIERS
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]
USDMF
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]NDC API
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Listed Suppliers
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]API Reference Price
API/FDF Prices: Book a Demo to explore the features and consider upgrading later
API Imports and Exports
| Importing Country | Total Quantity (KGS) |
Average Price (USD/KGS) |
Number of Transactions |
|---|
Upgrade, download data, analyse, strategize, subscribe with us 
Drugs in Development
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Digital Content
NEWS #PharmaBuzz
Market Place
ABOUT THIS PAGE
26
PharmaCompass offers a list of Tegoprazan API manufacturers, exporters & distributors, which can be sorted by GMP, USDMF, JDMF, KDMF, CEP (COS), WC, Price,and more, enabling you to easily find the right Tegoprazan manufacturer or Tegoprazan supplier for your needs.
Send us enquiries for free, and we will assist you in establishing a direct connection with your preferred Tegoprazan manufacturer or Tegoprazan supplier.
PharmaCompass also assists you with knowing the Tegoprazan API Price utilized in the formulation of products. Tegoprazan API Price is not always fixed or binding as the Tegoprazan Price is obtained through a variety of data sources. The Tegoprazan Price can also vary due to multiple factors, including market conditions, regulatory modifications, or negotiated pricing deals.
A Tegoprazan manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Tegoprazan, including repackagers and relabelers. The FDA regulates Tegoprazan manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Tegoprazan API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
click here to find a list of Tegoprazan manufacturers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PhamaCompass.
A Tegoprazan supplier is an individual or a company that provides Tegoprazan active pharmaceutical ingredient (API) or Tegoprazan finished formulations upon request. The Tegoprazan suppliers may include Tegoprazan API manufacturers, exporters, distributors and traders.
click here to find a list of Tegoprazan suppliers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PharmaCompass.
A Tegoprazan DMF (Drug Master File) is a document detailing the whole manufacturing process of Tegoprazan active pharmaceutical ingredient (API) in detail. Different forms of Tegoprazan DMFs exist exist since differing nations have different regulations, such as Tegoprazan USDMF, ASMF (EDMF), JDMF, CDMF, etc.
A Tegoprazan DMF submitted to regulatory agencies in the US is known as a USDMF. Tegoprazan USDMF includes data on Tegoprazan's chemical properties, information on the facilities and procedures used, and details about packaging and storage. The Tegoprazan USDMF is kept confidential to protect the manufacturer’s intellectual property.
click here to find a list of Tegoprazan suppliers with USDMF on PharmaCompass.
In Korea, the Ministry of Food and Drug Safety (MFDS) is in charge of regulating pharmaceutical products and services.
Pharmaceutical companies submit a Tegoprazan Drug Master File in Korea (Tegoprazan KDMF) to the MFDS, which includes comprehensive information about the production, processing, facilities, materials, packaging, and testing of Tegoprazan. The MFDS reviews the Tegoprazan KDMF as part of the drug registration process and uses the information provided in the Tegoprazan KDMF to evaluate the safety and efficacy of the drug.
After submitting a Tegoprazan KDMF to the MFDS, the registered manufacturer can provide importers or distributors with the registration number without revealing confidential information to Korean business partners. Applicants seeking to register their Tegoprazan API can apply through the Korea Drug Master File (KDMF).
click here to find a list of Tegoprazan suppliers with KDMF on PharmaCompass.
National Drug Code is a comprehensive database maintained by the FDA that contains information on all drugs marketed in the US. This directory includes information about finished drug products, unfinished drug products, and compounded drug products, including those containing Tegoprazan as an active pharmaceutical ingredient (API).
The FDA updates the NDC directory daily. The NDC numbers for Tegoprazan API and other APIs are published in this directory by the FDA.
The NDC unfinished drugs database includes product listing information submitted for all unfinished drugs, such as active pharmaceutical ingredients (APIs), drugs intended for further processing and bulk drug substances for compounding.
Pharmaceutical companies that manufacture Tegoprazan as an active pharmaceutical ingredient (API) must furnish the FDA with an updated record of all drugs that they produce, prepare, propagate, compound, or process for commercial distribution in the US at their facilities.
The NDC directory also contains data on finished compounded human drug products that contain Tegoprazan and are produced by outsourcing facilities. While these outsourcing facilities are not mandated to assign a Tegoprazan NDC to their finished compounded human drug products, they may choose to do so.
click here to find a list of Tegoprazan suppliers with NDC on PharmaCompass.
Tegoprazan Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of Tegoprazan GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right Tegoprazan GMP manufacturer or Tegoprazan GMP API supplier for your needs.
A Tegoprazan CoA (Certificate of Analysis) is a formal document that attests to Tegoprazan's compliance with Tegoprazan specifications and serves as a tool for batch-level quality control.
Tegoprazan CoA mostly includes findings from lab analyses of a specific batch. For each Tegoprazan CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
Tegoprazan may be tested according to a variety of international standards, such as European Pharmacopoeia (Tegoprazan EP), Tegoprazan JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Tegoprazan USP).
